	US 12,258,383 B2
	Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
Claudia Ania Penafuerte Diaz, Montreal (CA)
Assigned to Cura Therapeutics Inc., Montreal (CA)
Filed by Cura Therapeutics, Inc., Montreal (CA)
Filed on Jun. 30, 2022, as Appl. No. 17/810,128.
Application 17/810,128 is a division of application No. 17/574,479, filed on Jan. 12, 2022, granted, now 11,407,814.
Application 17/574,479 is a continuation of application No. PCT/US2021/055646, filed on Oct. 19, 2021.
Claims priority of provisional application 63/094,277, filed on Oct. 20, 2020.
Prior Publication US 2023/0023954 A1, Jan. 26, 2023
Int. Cl. A61K 38/00 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/71 (2006.01); C07K 19/00 (2006.01)

CPC C07K 14/71 (2013.01) [A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C07K 2319/32 (2013.01)]

16 Claims

1. A method of inhibiting or reducing tumor growth, tumor progression, or both, in a subject having a solid tumor, the method comprising: administering to the subject a fusion polypeptide comprising:

(a) an interleukin-2 (IL-2) polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 or SEQ ID NO: 3;

(b) a first soluble TGFβ receptor II (sTBRII) polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 8 or SEQ ID NO: 9; and

(c) a second soluble TGFβ receptor II (sTBRII) polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 8 or SEQ ID NO: 9,

thereby inhibiting or reducing tumor growth, tumor progression, or both, in the subject.